Magazine article Clinical Psychiatry News

Mifepristone May Limit Weight Gain from Antipsychotics

Magazine article Clinical Psychiatry News

Mifepristone May Limit Weight Gain from Antipsychotics

Article excerpt

PHOENIX -- The cortisol antagonist mifepristone significantly decreased weight gain associated with the second-generation antipsychotic olanzapine in a randomized, controlled pilot study in 57 healthy men.

Approved by the Food and Drug Administration as a medical abortion drug, mifepristone (Mifeprex) is a potent type-II glucocorticoid receptor antagonist.

In the study, lean, healthy men were randomized to 2 weeks of taking olanzapine 7.5 mg/day (22 men), olanzapine plus mifepristone 600 mg/day (24 men), or mifepristone plus placebo (11 men) in an institutional setting.

Those who were in the olanzapine group gained an average of 7 pounds, which was significantly more than the 5-pound gains seen in the combination group or mifepristone-only group, Dr. Joseph K. Belanoff and his associates reported at a meeting of the New Clinical Drug Evaluation Unit sponsored by the National Institute for Mental Health.

Comparing just the olanzapine group with the olanzapine-plus-mifepristone group, adding mifepristone seemed to mitigate the metabolic effects of olanzapine, according to Dr. Belanoff, who serves as chief executive officer of Corcept Therapeutics, the company that markets mifepristone. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.